NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and its subsidiary, HOPE Therapeutics, Inc., are making a major move in mental health care with the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California. Announced today, the definitive agreement marks a strategic expansion for NRXP, positioning Kadima as the clinical model for HOPE’s planned network of interventional psychiatry clinics across the U.S.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague.

Kadima, renowned for its integration of advanced clinical care and research, particularly in psychedelic medications and transcranial magnetic stimulation (TMS), will now anchor HOPE’s ambitious nationwide rollout. The acquisition is expected to immediately boost both revenue and EBITDA, bringing profitability to the group.

Dr. David Feifel, Kadima’s founder and a recognized leader in interventional psychiatry, will join HOPE Therapeutics as Chief Medical Innovation Officer. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)’s broader pipeline includes investigational drugs for suicidal bipolar depression and chronic pain.

HOPE Therapeutics aims to acquire 30 clinics by the end of 2025, with a projected $100 million in annual revenue. Kadima’s comprehensive treatment offerings for suicidal depression, PTSD, and other mental health conditions set a new standard for the company’s expanding footprint in psychiatric care.

While we acknowledge the potential of NRXP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than NRXP and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.